Search results
What's Going On With Iovance Biotherapeutics Today? - Iovance Biotherapeutics (NASDAQ:IOVA)
Benzinga· 3 days agoOn Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation ...
Tumor mutations may not predict response to immunotherapy, study finds
Medical Xpress· 4 days agoThe findings, published in Nature Cancer, upend long-held conventional wisdom and could lead to more effective ways of deciding which patients will benefit most from this type of treatment.
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual...
FOX21 Colorado Springs· 4 days agoEli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor ...
Author Correction: Developmental origins shape the paediatric cancer genome - Nature Reviews Cancer
Nature· 6 days agoCorrection to: Nature Reviews Cancer https://doi.org/10.1038/s41568-024-00684-9, published online 2 May 2024In the version of the article initially published, in the second paragraph of the ...
Nasdaq Gains 1%; Intuit Shares Plunge - Intuit (NASDAQ:INTU)
Benzinga· 3 days agoShares of Merus N.V. MRUS got a boost, surging 37% to $60.37 after the company announced the...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoSALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies
Crude Oil Rises 1%; Verastem Shares Slide - Verastem (NASDAQ:VSTM)
Benzinga· 3 days agoShares of Merus N.V. MRUS got a boost, surging 34% to $58.86 after the company announced the...
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks...
Benzinga· 3 days agoHere are some other big stocks recording gains in today's session. Merus N.V. MRUS jumped 30% to $57.26 after the company announced the publication of an abstract regarding petosemtamab in combination ...
ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations
FierceBiotech· 3 days agoAnalysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days ago- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00